Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
200estimated
Sites
33
Countries
Australia, France, Hong Kong +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-01 | actual | When the study began enrolling |
| Primary completion | 2023-07-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2020-08-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cholangiocarcinoma
- Chondrosarcoma
- Glioma
- Any Solid Tumor
Interventions
- Drug: LY3410738
- Drug: Gemcitabine — also filed as LY188011
- Drug: Cisplatin
- Drug: Durvalumab
Primary outcome
what the primary-completion date above is the date OFRecommended Phase 2 Dose (RP2D)
measured Up to 24 months
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed